The taxanes: toxicity and quality of life considerations in advanced ovarian cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6601496.pdf
Reference43 articles.
1. Aventis Pharmaceuticals Products Inc. Taxotere® (docetaxel) for injection concentrate (2002) Bridgewater, NJ
2. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM (2000) Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (3 Part 1) 78: 302–308
3. Boehnke Michaud L, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23: 401–428
4. Cull A, Howat S, Greimel E, Waldenstrom A-C, Arraras J, Kudelka A, Chauvenet L, Gould A, for the EORTC Quality of Life Group and the Scottish Gynaecological Cancer Trials Group (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47–53
5. du Bois A, Lück H, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320–1329
Cited by 76 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Moxibustion combined with guasha therapy for recurrent neutropenia following multiple cycles of chemotherapy of ovarian cancer: A case report;EXPLORE;2024-09
2. A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles;Cureus;2024-04-29
3. Aptamers for the Delivery of Plant-Based Compounds: A Review;Pharmaceutics;2024-04-14
4. Epithelial Ovarian Cancer;Tata Memorial Centre Textbook of Oncology;2024
5. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study;Clinical Cancer Research;2023-11-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3